Smith, Matthew RHussain, MahaSaad, FredFizazi, KarimSternberg, Cora NCrawford, E DavidKopyltsov, EvgenyPark, Chandler HAlekseev, BorisMontesa-Pino, AlvaroYe, DingweiParnis, FrancisCruz, FelipeTammela, Teuvo L JSuzuki, HiroyoshiUtriainen, TapioFu, ChengUemura, MotohideMendez-Vidal, Maria JMaughan, Benjamin LJoensuu, HeikkiThiele, SilkeLi, RuiKuss, IrisTombal, Bertrand2023-05-032023-05-032022-02-17Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar 24;386(12):1132-1142http://hdl.handle.net/10668/19663Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown. In this international, phase 3 trial, we randomly assigned patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive darolutamide (at a dose of 600 mg [two 300-mg tablets] twice daily) or matching placebo, both in combination with androgen-deprivation therapy and docetaxel. The primary end point was overall survival. The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 25, 2021), the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups.enNeutropeniaProportional hazards modelsProstatic neoplasmsProstatic neoplasms, castration-resistantPyrazolesAgedAged, 80 and overAndrogen antagonistsAndrogen receptor antagonistsAntineoplastic agentsDocetaxelDrug therapy, combinationHumansKaplan-Meier estimateMaleMiddle agedNeoplasm metastasisresearch article35179323open accessAntagonistas de andrógenosAntagonistas de receptores androgénicosAntineoplásicosEstimación de Kaplan-MeierMetástasis de la neoplasiaQuimioterapia combinada10.1056/NEJMoa21191151533-4406PMC9844551https://biblio.ugent.be/publication/01GQFQSK145J0MEJJQCRQKK6X9/file/01GRRACNDPT77BXSWKVJ9B6RV6.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844551/pdf